Cargando…
An EMT-Related Gene Signature for Predicting Response to Adjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma
BACKGROUND: For pancreatic ductal adenocarcinoma (PDAC) patients, chemotherapy failure is the major reason for postoperative recurrence and poor outcomes. Establishment of novel biomarkers and models for predicting chemotherapeutic efficacy may provide survival benefits by tailoring treatments. METH...
Autores principales: | Feng, Zengyu, Li, Kexian, Lou, Jianyao, Wu, Yulian, Peng, Chenghong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119901/ https://www.ncbi.nlm.nih.gov/pubmed/33996821 http://dx.doi.org/10.3389/fcell.2021.665161 |
Ejemplares similares
-
A Novel DNA Replication-Related Signature Predicting Recurrence After R0 Resection of Pancreatic Ductal Adenocarcinoma: Prognostic Value and Clinical Implications
por: Feng, Zengyu, et al.
Publicado: (2021) -
Development and Validation of a 7-Gene Prognostic Signature to Improve Survival Prediction in Pancreatic Ductal Adenocarcinoma
por: Feng, Zengyu, et al.
Publicado: (2021) -
A Novel Ferroptosis-Related Gene Signature Predicts Recurrence in Patients With Pancreatic Ductal Adenocarcinoma
por: Feng, Zengyu, et al.
Publicado: (2021) -
Transcriptomic Profiling Identifies DCBLD2 as a Diagnostic and Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma
por: Feng, Zengyu, et al.
Publicado: (2021) -
Development and validation of a cancer stem cell-related signature for prognostic prediction in pancreatic ductal adenocarcinoma
por: Feng, Zengyu, et al.
Publicado: (2020)